Search results for "Colore"

showing 10 items of 1250 documents

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?

2018

The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and expert discussion, Professor Cervantes summarizes the findings of numerous Phase II trials testing neoadjuvant chemotherapy. The crucial points in the next phase of trials include: patient selection, whether radiotherapy can be omitted altogether and whether chemotherapy can be used to augment the initial response to chemoradiotherapy. Finally, with the emergence of Magnetic Resonance Tumour Regression Grade a reliable method for assessing response after initial chemoradiotherapy, we ask if this can be used to drive the use of further sele…

Male0301 basic medicineOncologymedicine.medical_specialtyConsensusColorectal cancermedicine.medical_treatmentRisk AssessmentDisease-Free SurvivalSession (web analytics)law.invention03 medical and health sciencesClinical Trials Phase II as Topic0302 clinical medicineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CaremedicineHumansPreoperative chemotherapyChemotherapyProctectomyRectal Neoplasmsbusiness.industryGastroenterologyPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisNeoadjuvant TherapyRadiation therapyTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisFemaleAugmentbusinessChemoradiotherapyColorectal Disease
researchProduct

Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status

2019

The CD274 (programmed cell death ligand-1, PD-L1)/PDCD1 (programmed cell death-1, PD-1) pathway is crucial suppressor of the cytotoxic immune response. Antibodies targeting CD274 or PDCD1 have been revealed to be effective in several malignancies. In colorectal cancer, the response to CD274/PDCD1 blockage is associated with microsatellite instability. However, the value of CD274/PDCD1 for predicting response to treatment or survival benefit is still unclear. The aims of the study were (1) to clarify differences in immune microenvironment and expression of checkpoint proteins (CD274/PDCD1) in DNA mismatch repair-proficient, mismatch repair-deficient, and hereditary Lynch syndrome-associated …

Male0301 basic medicineOncologymedicine.medical_specialtyPathologyColorectal cancerProgrammed Cell Death 1 ReceptorCellDNA Mismatch RepairB7-H1 AntigenPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemInternal medicinePD-L1Biomarkers TumorTumor MicroenvironmentmedicineHumansCytotoxic T cellAgedbiologybusiness.industryMicrosatellite instabilityMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposis030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinFemaleDNA mismatch repairAntibodyColorectal Neoplasmsbusiness
researchProduct

Activated Thyroid Hormone Promotes Differentiation and Chemotherapeutic Sensitization of Colorectal Cancer Stem Cells by Regulating Wnt and BMP4 Sign…

2016

Abstract Thyroid hormone is a pleiotropic factor that controls many cellular processes in multiple cell types such as cancer stem cells (CSC). Thyroid hormone concentrations in the blood are stable, but the action of the deiodinases (D2–D3) provides cell-specific regulation of thyroid hormone activity. Deregulation of deiodinase function and thyroid hormone status has been implicated in tumorigenesis. Therefore, we investigated the role of thyroid hormone metabolism and signaling in colorectal CSCs (CR-CSC), where deiodinases control cell division and chemosensitivity. We found that increased intracellular thyroid hormone concentration through D3 depletion induced cell differentiation and s…

Male0301 basic medicineThyroid Hormonesendocrine systemCancer Researchmedicine.medical_specialtyendocrine system diseasesCellular differentiationDeiodinaseBone Morphogenetic Protein 4Colorectal NeoplasmMice03 medical and health sciencesCancer stem cellCell Line TumorInternal medicinemedicineAnimalsHumansThyroid HormoneWnt Signaling PathwayHormone activityThyroid hormone receptorbiologyAnimalThyroidWnt signaling pathwayCell DifferentiationMiddle Aged030104 developmental biologyEndocrinologymedicine.anatomical_structureOncologyNeoplastic Stem CellsCancer researchbiology.proteinNeoplastic Stem CellColorectal NeoplasmsHumanSignal TransductionHormoneCancer Research
researchProduct

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer

2018

Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 8…

Male0301 basic medicineTime FactorsColorectal cancerBLOCKADEGene DosageCetuximabmedicine.disease_causeAntineoplastic Agents Immunological0302 clinical medicinePREDICTS RESPONSEMedicineHETEROGENEITYBENEFITCopy-number variationEpidermal growth factor receptorIn Situ Hybridization FluorescenceAged 80 and overbiologyPanitumumabvasta-aineetMiddle AgedImmunohistochemistry3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeRAS MUTATIONSChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleKRASAntibodyColorectal NeoplasmsAdultgene copy numbermedicine.drug_classCETUXIMAB THERAPY3122 Cancerssilver in situ hybridizationDown-Regulationcolorectal cancerIn situ hybridizationAdenocarcinomaMonoclonal antibodyta3111Pathology and Forensic MedicineProto-Oncogene Proteins p21(ras)03 medical and health sciencesKRASHumansWILD-TYPEMETAANALYSISAgedRetrospective Studiessyöpähoidotbusiness.industrymedicine.diseaseta3122Blockadeperäsuolisyöpä030104 developmental biologymonoclonal antibodyMutationCancer researchbiology.protein3111 BiomedicineNeoplasm Recurrence Localbusinessepidermal growth factor receptorACQUIRED-RESISTANCEHuman Pathology
researchProduct

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct

Smart copolymer coated SPIONs for colon cancer chemotherapy

2019

Human colon cancer is one of the higher aggressive solid tumors, whose high mortality, much like many other solid tumors, results from metastasis formation. To reduce this high mortality, more effective chemotherapy, allowing a specific tumor accumulation and an efficient early-stage medical imaging as well, are still needed. At this regard, stimuli-responsive nanocarriers for anticancer drug delivery are promising strategy in cancer therapy. For this purpose, a dual targeted redox-responsive drug delivery system, prepared by coating superparamagnetic nanoparticles (SPIONs) with the amphiphilic copolymer INU-LA-PEG-FA and loading doxorubicin (DOXO-SPIONs) was investigated as tool for solid …

Male3003Colorectal cancerPolymersmedicine.medical_treatmentPharmaceutical ScienceMice Nude02 engineering and technologyDual targeting030226 pharmacology & pharmacyPolyethylene Glycols03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineDrug Delivery SystemsFolic AcidmedicineAnimalsHumansDoxorubicinReceptorMagnetite NanoparticlesRedox-responsiveChemotherapyAntibiotics Antineoplasticmedicine.diagnostic_testThioctic AcidInulinSPIONMagnetic resonance imaging021001 nanoscience & nanotechnologymedicine.diseaseMagnetic Resonance ImagingXenograft Model Antitumor AssaysUp-RegulationLipoic acidchemistryDoxorubicinSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryColonic NeoplasmsCancer researchCancer chemotherapyNanocarriers0210 nano-technologyOxidation-Reductionmedicine.drugMRI
researchProduct

TRATTAMENTO ENDOSCOPICO DEI POLIPI DEL COLON-RETTO IN UN AMBULATORIO DI ENDOSCOPIA DIGESTIVA:NOSTRA ESPERIENZA

2004

The aim of this report was to evaluate the effectiveness of the endoscopic treatment of colonic polyps to allow secondary prophylaxis in order to prevent the onset of cancer arising from adenomas. From October 2002 to January 2004 we performed 487 colonoscopies on a patient group with the following indications: screening prior to kidney transplant; screening for colorectal cancer (patients positive at faecal occult blood testing); follow-up of patients who had undergone colonic resections for colorectal cancer; patients with other diseases. Colorectal polyps were diagnosed in 15 males and 15 females, with a mean age of 63 years. All the neoplasms were resected during colonoscopy and specime…

MaleAmbulatory Surgical ProcedureColonic PolypIntestinal PolypFemaleAmbulatory Surgical Procedures Colonoscopy Colonic Polyps/*surgery Colorectal Neoplasms/*surgery Intestinal Polyps/surgeryColorectal NeoplasmColonoscopyMiddle AgedHuman
researchProduct

Enhanced Activity of Meprin-α, a Pro-Migratory and Pro-Angiogenic Protease, in Colorectal Cancer

2011

Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is not known. We investigated the effect of this protease on cell migration and angiogenesis in vitro and studied the expression of meprin-α mRNA, protein and proteolytic activity in primary tumors at progressive stages and in liver metastases of patients with colorectal cancer, as well as inhibitory activity towards meprin-α in sera of cancer patient as compared to healthy controls. We found that the hepatocyte growth factor (HGF)- induced migratory response of meprin-transfected epithelial c…

MaleAngiogenesisColorectal cancerCancer TreatmentGene Expressionlcsh:MedicineBiochemistry0302 clinical medicineCell MovementMolecular Cell BiologyGastrointestinal CancersMorphogenesisPathologylcsh:ScienceAged 80 and over0303 health sciencesMetalloproteinaseMultidisciplinaryHepatocyte Growth FactorLiver NeoplasmsMetalloendopeptidasesMiddle AgedImmunohistochemistryRecombinant ProteinsEnzymes3. Good healthOncology030220 oncology & carcinogenesisMedicineFemaleHepatocyte growth factorAntiangiogenesis TherapyColorectal NeoplasmsResearch Articlemedicine.drugAdultmedicine.medical_specialtyImmunoblottingHistopathologyNeovascularization PhysiologicCell MigrationGastroenterology and HepatologyIn Vitro TechniquesBiologyMannose-Binding LectinCell LineRectal CancerYoung Adult03 medical and health sciencesDogsDiagnostic MedicineInternal medicineGastrointestinal TumorsmedicineAnimalsHumansImmunoprecipitationBiologyAged030304 developmental biologylcsh:RCancers and NeoplasmsCancerPlasminogenBlotting Northernmedicine.diseaseRatsEndocrinologyAnatomical PathologyTumor progressionZymogen activationCancer cellCancer researchlcsh:QDevelopmental BiologyPLoS ONE
researchProduct

5-Fluorouracil plus interferon α-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: A multicentric randomized study

1998

Biochemical modulation is one of the most interesting fields in cancer chemotherapy. Interferon-alpha (IFNalpha) is a cytokine that is able to influence the pharmacodynamics of 5-fluorouracil (5FU) through a number of mechanisms. With the aim of confirming some data emerging from the literature, we initiated a multicentric randomized study comparing the combination of 5FU and IFNalpha-2a with 5FU alone in the treatment of advanced or metastatic colon cancer. A group of 205 colon cancer patients (104 in the 5FU arm and 101 in the 5FU + IFNapha-2a arm) were included in the final intention-to-treat analysis. Rectal cancers were not considered eligible. All patients had measurable disease, were…

MaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyColorectal cancerAlpha interferonInterferon alpha-2GastroenterologyMetastasisInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansInterferon alfaAgedLeukopeniabusiness.industryStandard treatmentInterferon-alphaGeneral MedicineMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologyFluorouracilColonic NeoplasmsFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial

2021

Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared the effects of high- vs low-to-moderate-intensity exercise with or without additional behavior change support (BCS) on CRF in patients undergoing (neo-)adjuvant cancer treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo-)adjuvant treatment were randomized to high intensity (n = 144), low-to-moderate intensity (n = 144), high intensity with BCS (n = 144) or low…

MaleAnxiety030204 cardiovascular system & hematologyNeo adjuvantlaw.inventionTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineRandomized controlled trialBehavior TherapylawNeoplasmsActivities of Daily LivingOrthopedics and Sports MedicineSjukgymnastikPhysiotherapyCancer-related fatigueLicenseFatigueDepressionCreative commonsMiddle AgedVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850Neoadjuvant TherapyExercise TherapyCancer treatmentEndurance TrainingCardiorespiratory FitnessVDP::Medisinske Fag: 700::Helsefag: 800Femalemedicine.symptomColorectal NeoplasmsPsychologybehavior change; cancer‐ related fatigue; endurance training; oncology; resistance trainingmedicine.medical_specialtyBreast NeoplasmsPhysical Therapy Sports Therapy and Rehabilitation03 medical and health sciencesmedicineHumansMuscle StrengthCancer och onkologiResistance trainingProstatic NeoplasmsResistance Training030229 sport sciencesCancer and OncologyQuality of LifeExercise intensityPhysical therapySedentary BehaviorSleep
researchProduct